Short Communication: Impaired Fitness of Foscarnet-Resistant Strains of Human Immunodeficiency Virus Type 1
- 10 August 1998
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 14 (12) , 1059-1064
- https://doi.org/10.1089/aid.1998.14.1059
Abstract
Foscarnet (PFA) is a pyrophosphate analogue antiviral active against human immunodeficiency virus (HIV-1) and herpesviruses. Strains of HIV-1 resistant to PFA have mutations in the HIV-1 reverse transcriptase (RT). We examined the influence of PFA resistance mutations, in different genetic backgrounds, on HIV-1 replication competency in both replication kinetics and growth competition assays. In replication kinetics assays, the recombinant strains HX89K, HX92I, and HX156A (encoding RT mutations E89K, L92I, and S156A, respectively, in the HXB2-D genetic background) replicated to lower titers than the wild-type parent in the absence of drug, and the degree of replication impairment increased as PFA resistance increased. PFA-resistant strains LAI 921 and LAI 156A (encoding RT mutations L92I and S156A, respectively) were replication impaired in comparison to the wild-type parent LAI to a similar degree as observed for strains in the HXB2D background. In growth competition assays with wild-type LAI, strains LAI 921 and LAI 156A had relative fitness values of 0.5 and 0.8, respectively. These results show that the RT mutations E89K, L92I and S156A, observed in PFA-resistant strains selected in cell culture, reduce replication competence. Furthermore, these data show a correlation of increasing PFA resistance and decreasing replication competence mediated by single amino acid substitutions in the RT.Keywords
This publication has 44 references indexed in Scilit:
- Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteinsAntiviral Research, 1996
- Foscarnet Decreases Human Immunodeficiency Virus RNAThe Journal of Infectious Diseases, 1995
- Rapid Changes in Human Immunodeficiency Virus Type 1 RNA Load and Appearance of Drug-Resistant Virus Populations in Persons Treated with Lamivudine (3TC)The Journal of Infectious Diseases, 1995
- Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolatesAntimicrobial Agents and Chemotherapy, 1995
- Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapyNature, 1993
- Mutational analysis of two conserved sequence motifs in HIV‐1 reverse transcriptaseFEBS Letters, 1991
- Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)Science, 1989
- Antiviral effects of phosphonoformate (pfa, foscarnet sodium)Pharmacology & Therapeutics, 1989
- Site-specific mutagenesis of AIDS virus reverse transcriptaseNature, 1987
- Infection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque AssayScience, 1985